



**MEDI-CAL DRUG USE REVIEW (DUR) BOARD**

***State of California***  
**DEPARTMENT OF HEALTH CARE SERVICES**

Notice is hereby given that the **Medi-Cal DUR Board** will conduct a public meeting on **Tuesday, February 14, 2012**, at the following location:

Medi-Cal Drug Use Review Board  
 Meeting Agenda  
 February 14, 2012  
 10:30 AM-1:00 PM  
 DHCS Training Room B+C  
 1500 Capitol Avenue  
 Sacramento, CA 95814

Report Type*	Agenda Item	Presenter	Time
C	<ol style="list-style-type: none"> <li>1. Welcome</li> <li>2. Introduce New Board Chair</li> </ol>	Pauline Chan, RPh	1030
A	<ol style="list-style-type: none"> <li>3. Call to Order/Review and Approval of Previous Minutes November 15, 2011</li> <li>4. Vice-Chair Election</li> </ol>	Marilyn Stebbins, Pharm.D.	1040-1050
	<ol style="list-style-type: none"> <li>5. Old Business</li> </ol>		
A	<ol style="list-style-type: none"> <li>a. Review of Action Items From Previous Board Meeting:               <ol style="list-style-type: none"> <li>i. Volunteers from Board to work on redesign of DUR quarterly report</li> <li>ii. For February meeting, present ACS's experience with DUR programs in other states</li> <li>iii. Unapproved Cough, Cold, Allergy Products: FDA Prompts Removal From Market article to website</li> <li>iv. Present components of trend at the dose level for a specific drug, like aripiprazole</li> <li>v. Present data on simvastatin drug interactions</li> <li>vi. Board requests CalMend data to develop a potential educational article. In addition, the Board would like reports for the 0-6 year old group.</li> </ol> </li> </ol>	Pauline Chan, RPh	1050-1110

	<b>6.</b> New Business		
I	<b>a.</b> ACS's experience with DUR programs in other states	Robert Berringer, PharmD	1110-1135
R	<b>b.</b> DHCS Update <b>i.</b> Policy update <b>ii.</b> Psychotropic medication use amongst children and adolescents in foster care: state summary report. <b>iii.</b> HHS guidance on psychotropic medication use amongst children and adolescents in foster care <b>iv.</b> Center for Health Care Strategies Quality Improvement Collaborative <b>v.</b> DUR Manual Section 15 - DRAFT REVISION - Retrospective Drug use Review	Pauline Chan, RPh	1135-1200
R	<b>c.</b> ACS/UCSF Update <b>i.</b> DUR quarterly report (October-December 2011) <b>ii.</b> Present additional data on simvastatin drug interactions <b>iii.</b> Medi-Cal Bulletin: <a href="#">An Overview of Treatment Approaches to Insomnia</a> – January 2012	Patrick Robinson, RPh  Shalini Lynch, PharmD	1200-1220
R	<b>d.</b> Board Member Projects <b>i.</b> Anti-depressants <b>ii.</b> Intervention Work Group <b>iii.</b> Target Drug List Work Group <b>iv.</b> Quarterly Report Revision <b>v.</b> Simvastatin alert		1220-1235
D	<b>e.</b> E-prescribing adoption in California <b>i.</b> Electronic Prescribing Adoption and Use <b>ii.</b> Partners in E Project	Lisa Ashton, PharmD	1235-1250
C	<b>7.</b> Board Members & Public Comments**		1250-1300
	<b>8.</b> Consent Agenda		
I	<b>a.</b> Meeting Feedback <b>i.</b> Time allocation from 10:30 AM to 1:00 PM <b>b.</b> Next Meeting: <b>May 22, 2012</b> <b>10:30AM-1:00PM</b> <b>Place: Room 2011</b> <b>1501 Capitol Avenue,</b> <b>Sacramento, CA 95814</b> <b>c.</b> Closing Remarks		1300
	<b>9.</b> Adjournment		1300

\* REPORT TYPE LEGEND: A: Action; R: Report; I: Information; C: Comment; D: Discussion

\*\* Comments from the public are always appreciated. However, comments will be limited to five minutes per individual.

Picture identification is required to gain access into the California Department of Health Services building. However, your security information will not be provided to the DUR Board.

You can obtain the DUR Board agenda from the Medi-Cal DUR Main Menu Web site ([http://files.medi-cal.ca.gov/pubsdoco/dur/dur\\_home.asp](http://files.medi-cal.ca.gov/pubsdoco/dur/dur_home.asp)).